Issues

• 25 August 2026Issue 11Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.
• 18 August 2026Issue 10A clinician, not a company, runs Germany's psilocybin compassionate use programme
• 4 August 2026Issue 9No European application on file for the world's most advanced psilocybin programme
• 28 July 2026Issue 8Europe already pays for clinic-administered psychiatry. Just not for psychedelics.
• 21 July 2026Issue 7Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine
• 14 July 2026Issue 6Issue 6 / Week of 7-13 July 2026
• 7 July 2026Issue 5Issue 5 / Week of 30 June-6 July 2026
• 30 June 2026Issue 4Issue 4 / Week of 23-29 June 2026
• 23 June 2026Issue 3Issue 3 / Week of 16–22 June 2026
• 16 June 2026Issue 2Issue 2 / Week of 9-15 June 2026
• 11 June 2026European Psychedelic Medicine: H1 2026 in Review
• 9 June 2026Issue 1Psychedelic Brief
• 3 June 2026Why Psychedelic Brief Exists.